Bupivacaine

證據等級: L5

預測適應症: 10 個

Bupivacaine: From Local/Regional Anesthesia to Acrodermatitis Chronica Atrophicans

One-Sentence Summary

Bupivacaine is a long-acting amide-type local anesthetic widely used for regional anesthesia, epidural analgesia, and perioperative pain management. The TxGNN model predicts it may be effective for Acrodermatitis Chronica Atrophicans (a late cutaneous manifestation of Lyme borreliosis), with 0 clinical trials and 0 publications currently supporting this direction — the prediction appears driven by knowledge graph proximity rather than a mechanistic rationale.

Quick Overview

Item	Content
Original Indication	Local/regional anesthesia and pain management
Predicted New Indication	Acrodermatitis Chronica Atrophicans
TxGNN Prediction Score	99.23%
Evidence Level	L5
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacological information, Bupivacaine is a long-acting amide-class local anesthetic that primarily blocks voltage-gated sodium channels (Nav1.7, Nav1.8), thereby preventing depolarisation and inhibiting nerve impulse conduction. Beyond its anesthetic effect, preclinical studies have reported that bupivacaine may modulate local inflammatory signalling — including suppression of NF-κB activation and reduced release of pro-inflammatory cytokines (TNF-α, IL-6) — at concentrations achievable within injected tissue.

Acrodermatitis chronica atrophicans (ACA) is the late-stage dermatological manifestation of Lyme borreliosis, caused by persistent Borrelia burgdorferi infection. The disease is characterised by chronic dermal lymphocytic infiltration, progressive skin atrophy, and collagen loss — driven primarily by ongoing spirochetal infection and the resulting host immune dysregulation, not by a purely inflammatory or channel-mediated process.

The mechanistic link between bupivacaine and ACA is implausible. ACA is fundamentally an infectious disease that responds to antibiotic therapy (doxycycline, amoxicillin); sodium channel blockade has no known role in clearing Borrelia or reversing the associated connective tissue destruction. The TxGNN score of 0.992 almost certainly reflects the model capturing a neighbourhood relationship between generic "skin inflammation" nodes in the knowledge graph — a non-specific signal rather than a genuine therapeutic hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug interaction data were not available in this evidence pack. Retrieval from the Singapore HSA package insert and DrugBank is required before any clinical evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (acrodermatitis chronica atrophicans) is an antibiotic-responsive infectious disease with no plausible biological connection to bupivacaine's mechanism of action; the evidence level is L5 (model prediction only), and no supporting clinical or preclinical literature exists.

To proceed, the following is needed:

Safety data gap closure (Blocking): Retrieve Singapore HSA / Taiwan TFDA package insert warnings and contraindications (DG001) before any further evaluation stage can be entered.
MOA data from DrugBank (High): Complete the DrugBank API query (DG002) to enable proper mechanistic linkage analysis across all predicted indications.
Re-prioritise the candidate list: Among the 10 predictions evaluated, two carry clinically coherent rationales and at least some supporting evidence:
- Rank 8 — Epulis / Central Giant Cell Granuloma (L4, Research Question): Six case-series publications document a specific intralesional protocol combining triamcinolone + bupivacaine for CGCG; bupivacaine serves as both a carrier vehicle and a post-injection analgesic, with one publication (PMID 11862204) explicitly reporting the bupivacaine mixture. This is the most clinically grounded finding in the pack.
- Rank 9 — Polyp of Vocal Cord (L4, Research Question): A Phase 2 RCT (NCT06734975, n=28, recruiting) is formally testing whether bupivacaine superior laryngeal nerve block improves patient outcomes following microdirect laryngoscopy for benign vocal fold lesions. The study design is rigorous; results are pending (expected completion December 2026).
Formal evaluation of Ranks 8–9 should be prioritised over Rank 1, as these represent actionable research questions rather than graph artefacts.

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.